KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
26.70
+7.46 (38.75%)
Apr 29, 2026, 10:08 AM EDT - Market open
Company Description
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs.
Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE).
The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients.
KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
KalVista Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 275 |
| CEO | Benjamin Palleiko |
Contact Details
Address: 200 Crossing Boulevard Framingham, Massachusetts 01702 United States | |
| Phone | 857 999 0075 |
| Website | kalvista.com |
Stock Details
| Ticker Symbol | KALV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001348911 |
| CUSIP Number | 483497103 |
| ISIN Number | US4834971032 |
| Employer ID | 20-0915291 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Palleiko | Chief Executive Officer and Director |
| Brian Piekos | Chief Financial Officer |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Bilal Arif | Chief Operating Officer |
| Ryan Baker | Head of Investor Relations |
| Brian Krex J.D. | General Counsel |
| Jarrod Aldom | Vice President of Corporate Communications |
| Linea Aspesi | Chief People Officer |
| Rachel M. Morten | Senior Vice President of Regulatory Affairs and QA |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 25, 2026 | 10-KT | Filing |
| Mar 25, 2026 | 8-K | Current Report |
| Jan 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jan 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | SCHEDULE 13G | Filing |
| Jan 8, 2026 | 8-K | Current Report |
| Dec 30, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 10, 2025 | 10-Q | Quarterly Report |
| Nov 10, 2025 | 8-K | Current Report |